ストックスクリーナーアプリを入手
1.8476
2.24%
-0.0424
アフターアワーズ：
1.85
0.0024
+0.13%
前日終値:
$1.89
開ける：
$1.87
24時間の取引高:
4,464
Relative Volume:
0.50
時価総額：
$28.62M
収益：
$22.06M
当期純損益:
$-30.94M
株価収益率:
-0.8248
EPS:
-2.24
ネットキャッシュフロー:
$-26.70M
1週間 パフォーマンス:
-1.20%
1か月 パフォーマンス:
-5.25%
6か月 パフォーマンス:
-53.20%
1年 パフォーマンス:
-52.18%
1日の値動き範囲:
$1.82
$1.87
1週間の範囲:
$1.7725
$1.92
52週間の値動き範囲:
$1.635
$7.67
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
CASI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
1.8476 | 29.28M | 22.06M | -30.94M | -26.70M | -2.24 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2021-04-26 | 開始されました | Mizuho | Buy |
| 2020-10-23 | 開始されました | Oppenheimer | Outperform |
| 2016-09-22 | 開始されました | Maxim Group | Buy |
| 2015-10-29 | 再開されました | H.C. Wainwright | Buy |
| 2015-06-23 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Casi Pharmaceuticals Inc (CASI) 最新ニュース
CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated by Analysts at StockNews.com - Defense World
HC Wainwright Has Positive Forecast for CASI Q2 Earnings - Defense World
Transcript : CASI Pharmaceuticals, Inc.Special Call - marketscreener.com
CASI to Host Business and Clinical Update Conference Call | CASI Stock News - GuruFocus
CASI Pharmaceuticals Schedules Business Update Amid Legal Proceedings - TipRanks
CASI Pharmaceuticals (NASDAQ:CASI) Given “Buy” Rating at HC Wainwright - Defense World
CASI Pharmaceuticals: HC Wainwright & Co. Reiterates Buy Rating - GuruFocus
CASI Pharmaceuticals Provides Business and Clinical Update - ACCESS Newswire
CASI Pharmaceuticals Schedules Major Business and Clinical Pipeline Review: What Investors Should Watch - Stock Titan
Kaixin Pharmaceuticals Inc. entered into a definitive Equity and Assets Transfer Agreement to acquire Two subsidiaries in China from CASI Pharmaceuticals, Inc. for $20 million. - marketscreener.com
CASI Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CASI Pharmaceuticals Reports Q1 2025 Results and Asset Divestiture in China - TipRanks
CASI Pharmaceuticals Sees Revenue Boost in Q1 and Advances Key Program | CASI Stock News - GuruFocus
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results - ACCESS Newswire
CASI Pharmaceuticals Exits China in $20M Deal While Posting Record 82% Revenue Growth - Stock Titan
CASI Pharmaceuticals appoints new CFO - Investing.com
CASI Pharmaceuticals appoints new CFO By Investing.com - Investing.com India
CASI Pharmaceuticals Announces CFO Transition - TipRanks
CASI Pharmaceuticals Inc Daniel Lang To Step Down From His Role As Co'S Chief Financial Officer - marketscreener.com
CASI Pharmaceuticals (NASDAQ:CASI) Earns Hold Rating from Analysts at StockNews.com - Defense World
CASI Pharmaceuticals divests equity in Chinese subsidiaries By Investing.com - Investing.com Canada
CASI Pharmaceuticals Enters Into Definitive Agreement To Divest Assets in China - citybiz
CASI to Divest Two Subsidiaries in China - marketscreener.com
CASI Pharmaceuticals (CASI) Sells Equity and Rights to Kaixin Ph - GuruFocus
CASI Pharmaceuticals Divests Chinese Assets in $20 Million Deal - TipRanks
CASI Pharmaceuticals divests equity in Chinese subsidiaries - Investing.com
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China - ACCESS Newswire
CASI Pharmaceuticals (CASI) to Release Earnings on Tuesday - Defense World
CASI Pharmaceuticals faces Nasdaq delisting over market value By Investing.com - Investing.com Nigeria
CASI Pharmaceuticals Faces Nasdaq Listing Compliance Challenge | CASI Stock News - GuruFocus
CASI Pharmaceuticals Faces Nasdaq Compliance Challenge - TipRanks
Casi Pharmaceuticals receives Nasdaq deficiency notice - TipRanks
CASI Pharmaceuticals faces Nasdaq delisting over market value - Investing.com Australia
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement - ACCESS Newswire
StockNews.com Begins Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - ACCESS Newswire
CASI Pharmaceuticals, Inc.Ordinary Shares (NQ: CASI - FinancialContent
Brokers Issue Forecasts for CASI Q1 Earnings - Defense World
StockNews.com Initiates Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
HC Wainwright Has Lowered Expectations for CASI Pharmaceuticals (NASDAQ:CASI) Stock Price - Defense World
CASI stock touches 52-week low at $1.88 amid market challenges - Investing.com
CASI Pharmaceuticals Moves to Arbitration in Dispute with Acrotech - TipRanks
CASI receives updated buyout offer for China operations - The Pharma Letter
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely - Asianet Newsable
CASI Pharma stock hits 52-week low at $1.9 amid market challenges - Investing.com Australia
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish - MSN
CASI Pharmaceuticals receives buyout proposal from CEO By Investing.com - Investing.com South Africa
Casi Pharmaceuticals Inc (CASI) 財務データ
収益
当期純利益
現金流量
EPS
6.48%
大文字化:
|
ボリューム (24 時間):